CytRx Corp., of Los Angeles, said the independent data safety monitoring committee overseeing the company's international Phase IIb trial with aldoxorubicin as a first-line treatment for patients with late-stage metastatic soft tissue sarcoma has recommended conducting the clinical trial through completion

Each independent data safety monitoring board recommended that each trial continue as planned

Gilead Sciences Inc., of Foster City, Calif., said the data and safety monitoring board recommended that the ongoing Phase III trial testing a once-daily fixed-dose combination of nucleotide sofosbuvir and NS5A inhibitor ledipasvir with and without ribavirin for 12 weeks or 24 weeks in treatment-naïve genotype 1 hepatitis C patients continue without modification

Advanced Cell Technology Inc., of Santa Monica, Calif., said an independent data and safety monitoring board authorized the firm to move forward with enrollment and treatment of patients in the next cohort of each of its three ongoing trials of human embryonic stem cell-derived retinal pigment epithelial cells for eye diseases

Inc., of Whitehouse Station, N.J., said the data safety monitoring board of the IMPROVE-IT trial testing cholesterol-lowering drug Vytorin (ezetimibe/simvastatin) completed its planned review and recommended that the study continue

The trial will enroll 60 to 70 patients for a 12-month treatment period followed by up to 90 days safety monitoring and follow-up...Protalex Inc., of Summit, N.J., said that following a planned interim safety review by a data safety monitoring committee, it will continue enrollment and dosing of patients in its Phase Ib trial of PRTX-100 in combination with methotrexate and leflunomide for rheumatoid arthritis

Inviragen Inc., of Fort Collins, Colo., said it started the second stage of its ongoing Phase II study testing DENVax, its dengue vaccine, following review and recommendation by the data safety monitoring board

Cell Therapeutics Inc., of Seattle, said an independent data safety monitoring board recommended continuation of a Phase III trial of Opaxo (paclitaxel poligumex) in ovarian cancer...CytRx Corp., of Los Angeles, said a data safety monitoring committee recommended continuing a Phase IIb trial of tamibarotene with chemotherapy in non-small-cell lung cancer

BHR Pharma LLC, of Herndon, Va., reported that an independed data and safety monitoring board evaluated safety data from 803 randomized patients from its SyNAPSe Trial of BHR-100 for traumatic brain injury, and it found no probems, recommending that the trial continue toward completion

Oxford BioMedica plc, of Oxford, UK, and partner Sanofi SA, of Paris, disclosed a positive interim review of the ongoing UshStat Phase I/IIa study by the data safety monitoring board (DSMB), with no serious adverse events in the three patients treated at dose level one related to the product...The data safety monitoring board previously approved starting cohort two of the planned three-cohort dose-escalation study

Diffusion Pharmaceuticals LLC, of Charlottesville, Va., said it completed a Phase I trial of lead compound trans sodium crocetinate (TSC) in nine patients with newly diagnosed primary glioblastoma (GBM), and a safety monitoring committee authorized immediate open enrollment for a follow-on Phase II trial

Advanced Cell Technology Inc. (ACT), of Marlborough, Mass., said the independent data and safety monitoring board for its three ongoing trials approved the enrollment and treatment of two additional patients with dry age-related macular degeneration, representing the final patients in the trial's three-patient second cohort

GTx Inc., of Memphis, Tenn., said an independent data safety monitoring board recommended that the firm continue development as planned with two pivotal Phase III studies testing enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with non-small-cell lung cancer, following a per-protocol interim safety review

Celgene Corp., of Summit, N.J., said its Celgene International Sarl subsidiary reported the data safety monitoring board (DSMB) determined that the Phase III study MM-003 testing pomalidomide plus low-dose dexamethasone compared to high-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma met the primary endpoint of improvement in progression-free survival (PFS) at the PFS final analysis

Advanced Cell Technology Inc., of Marlborough, Mass., said the data and safety monitoring board (DSMB) authorized the company to move forward with enrollment and treatment of second and third additional patients with Stargardt's macular dystrophy (SMD) in the second patient cohort of its U.S

Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., reported favorable results from the most recent safety monitoring committee review for the company's ongoing Phase III pivotal studies of NX-1207 in benign prostatic hyperplasia

The addition of 225 patients is in response to the recommendation of the trial's independent data and safety monitoring board (DSMB) following its pre-planned interim analysis of unblinded efficacy and safety datasets from the pivotal trial

ImmunoCellular expects the data safety monitoring committee to conduct an interim safety analysis when 32 events have occurred, which is anticipated in the first quarter of 2013

Oxford BioMedica plc, of Oxford, UK, and partner Sanofi SA, of Paris, reported a positive interim review by the data safety monitoring board (DSMB) of the RetinoStat Phase I study in neovascular, or wet, age-related macular degeneration and the StarGen Phase I/IIa study in Stargardt disease